Because of its widespread overexpression, B7-H3 is being actively pursued as an immunotherapeutic target: anti–B7–H3 CAR-T-cells and antibody–drug conjugates have shown anti-tumor activity in preclinical models of GBM, DIPG, and other pediatric brain tumors [16,17,18,19,20]. This evidence concerns the gene CD276 and diffuse intrinsic pontine glioma.